×

Sign up to our weekly newsletter

Subscribe!

EN

|

ES

Search

TecSalud

Sort by:

photo of a persona in a lab
A molecule created in conjunction with Cardiol Therapeutics is capable of interrupting the acute inflammatory response of patients with SARS-CoV-2.

TecSalud

photo of a persona in a lab
A molecule created in conjunction with Cardiol Therapeutics is capable of interrupting the acute inflammatory response of patients with SARS-CoV-2.

Sign up to our weekly newsletter!

Scientists, innovation and the stories that explain it all.